Plus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2 Trial Data at the 2024 Congress of Neurological Surgeons Annual Meeting (GlobeNewswire) - Sep 18, 2024 - "Plus Therapeutics, Inc...will present data at the 2024 Congress of Neurological Surgeons (CNS) Annual Meeting September 28 - October 2, in Houston, Texas."
P2 data • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor
|